These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21246582)

  • 1. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.
    Suzuki F; Suzuki Y; Akuta N; Sezaki H; Hirakawa M; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Chayama K; Kamatani N; Nakamura Y; Miyakawa Y; Kumada H
    Hepatology; 2011 Feb; 53(2):415-21. PubMed ID: 21246582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism of the inosine triphosphate pyrophosphatase gene predicts ribavirin-induced anemia in chronic hepatitis C patients.
    Nishimura T; Osaki R; Shioya M; Imaeda H; Aomatsu T; Takeuchi T; Okumura Y; Fujiyama Y; Andoh A
    Mol Med Rep; 2012 Feb; 5(2):517-20. PubMed ID: 22052220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.
    Ogawa E; Furusyo N; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Oct; 59(4):667-74. PubMed ID: 23707372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.
    Thompson AJ; Santoro R; Piazzolla V; Clark PJ; Naggie S; Tillmann HL; Patel K; Muir AJ; Shianna KV; Mottola L; Petruzzellis D; Romano M; Sogari F; Facciorusso D; Goldstein DB; McHutchison JG; Mangia A
    Hepatology; 2011 Feb; 53(2):389-95. PubMed ID: 21274861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.
    Morio K; Imamura M; Kawakami Y; Nakahara T; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Makokha GN; Ochi H; Amano H; Arataki K; Moriya T; Ito H; Tsuji K; Kohno H; Waki K; Tamura T; Nakamura T; Chayama K;
    J Gastroenterol; 2017 Jun; 52(6):746-753. PubMed ID: 27822709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C.
    El Raziky M; Zayed NA; Abdel Baki A; Mansour SA; Shahin RMH
    J Med Virol; 2017 Oct; 89(10):1823-1829. PubMed ID: 28480960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients.
    Ahmed WH; Furusyo N; Zaky S; Eldin AS; Aboalam H; Ogawa E; Murata M; Hayashi J
    World J Gastroenterol; 2013 Mar; 19(9):1387-95. PubMed ID: 23538996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.
    Matsuura K; Tanaka Y; Watanabe T; Fujiwara K; Orito E; Kurosaki M; Izumi N; Sakamoto N; Enomoto N; Yatsuhashi H; Kusakabe A; Shinkai N; Nojiri S; Joh T; Mizokami M
    J Viral Hepat; 2014 Jul; 21(7):466-74. PubMed ID: 24750345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.
    Kurosaki M; Tanaka Y; Tanaka K; Suzuki Y; Hoshioka Y; Tamaki N; Kato T; Yasui Y; Hosokawa T; Ueda K; Tsuchiya K; Kuzuya T; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Matsuura K; Sugauchi F; Enomoto N; Nishida N; Tokunaga K; Mizokami M; Izumi N
    Antivir Ther; 2011; 16(5):685-94. PubMed ID: 21817190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis.
    Pineda-Tenor D; García-Álvarez M; Jiménez-Sousa MA; Vázquez-Morón S; Resino S
    J Transl Med; 2015 Oct; 13():320. PubMed ID: 26438033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.
    Tahata Y; Hiramatsu N; Oze T; Urabe A; Morishita N; Yamada R; Yakushijin T; Hosui A; Oshita M; Kaneko A; Hagiwara H; Mita E; Ito T; Yamada Y; Inada M; Katayama K; Tamura S; Imai Y; Hikita H; Sakamori R; Yoshida Y; Tatsumi T; Hayashi N; Takehara T
    J Med Virol; 2016 Oct; 88(10):1776-84. PubMed ID: 26991414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment.
    DʼAvolio A; Ciancio A; Siccardi M; Smedile A; Baietto L; Simiele M; Marucco DA; Cariti G; Calcagno A; de Requena DG; Sciandra M; Cusato J; Troshina G; Bonora S; Rizzetto M; Di Perri G
    Ther Drug Monit; 2012 Apr; 34(2):165-70. PubMed ID: 22406654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between ITPA rs1127354 polymorphisms and efficacy of antiviral treatment in Northeast Chinese CHC patients.
    Liu Z; Wang S; Qi W; Wang X; Sun D; Wang H; Zhang Y; Li Z; Zhu L; Zhao P; Guo H; Zhou C; Wang J
    Medicine (Baltimore); 2017 Jul; 96(29):e7554. PubMed ID: 28723780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase in platelet count based on inosine triphosphatase genotype during interferon beta plus ribavirin combination therapy.
    Nomura H; Miyagi Y; Tanimoto H; Yamashita N; Ito K; Masaki N; Mizokami M
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1461-6. PubMed ID: 22554247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir.
    Boglione L; De Nicolò A; Cusato J; Cariti G; Di Perri G; D'Avolio A
    J Viral Hepat; 2014 Apr; 21(4):260-3. PubMed ID: 24597694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection.
    Rau M; Stickel F; Russmann S; Manser CN; Becker PP; Weisskopf M; Schmitt J; Dill MT; Dufour JF; Moradpour D; Semela D; Müllhaupt B; Geier A;
    J Hepatol; 2013 Apr; 58(4):669-75. PubMed ID: 23195617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.
    Azakami T; Hayes CN; Sezaki H; Kobayashi M; Akuta N; Suzuki F; Kumada H; Abe H; Miki D; Tsuge M; Imamura M; Kawakami Y; Takahashi S; Ochi H; Nakamura Y; Kamatani N; Chayama K
    J Med Virol; 2011 Jun; 83(6):1048-57. PubMed ID: 21503919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy.
    Kozuka R; Hai H; Teranishi Y; Motoyama H; Kawamura E; Hagihara A; Uchida-Kobayashi S; Morikawa H; Enomoto M; Murakami Y; Kawada N; Tamori A
    J Gastroenterol Hepatol; 2017 Aug; 32(8):1495-1502. PubMed ID: 28109022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.
    Domingo P; Guardiola JM; Salazar J; Torres F; Mateo MG; Pacho C; Del Mar Gutierrez M; Lamarca K; Fontanet A; Martin J; Muñoz J; Vidal F; Baiget M
    Antimicrob Agents Chemother; 2012 Jun; 56(6):2987-93. PubMed ID: 22430973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated-interferon and ribavirin.
    Hai H; Tamori A; Enomoto M; Morikawa H; Uchida-Kobayashi S; Fujii H; Hagihara A; Kawamura E; Thuy le TT; Tanaka Y; Kawada N
    J Gastroenterol Hepatol; 2014 Jan; 29(1):201-7. PubMed ID: 23980585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.